HLA-DR antibody

Catalog No. ABIN4949753

The Mouse Monoclonal anti-HLA-DR antibody (Clone IPO-10) (ABIN4949753) specifically detects HLA-DR in FACS and IF. The antibody is reactive with Human and Monkey samples.

Quick Overview for HLA-DR antibody (ABIN4949753)

Target: HLA-DR

Reactivity: Human, Monkey

Host: Mouse

Clonality: Monoclonal

Conjugate: This HLA-DR antibody is un-conjugated

Application: Flow Cytometry (FACS), Immunofluorescence (IF)

Clone: IPO-10

Product Details anti-HLA-DR Antibody

Purification: Protein G affinity chromatography

Immunogen: Spleen cells from a patient with hairy cell leukemia were used as the immunogen for the HLA-DR antibody.

Isotype: IgG3 kappa

Application Details

Application Notes: Optimal dilution of the HLA-DR antibody should be determined by the researcher.\. Flow Cytometry: 0.5-1 μg/million cells in 0.1ml,Immunofluorescence: 0.5-1 μg/mL

Restrictions: For Research Use only

Handling

Concentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Preservative: Azide free

Storage: 4 °C,-20 °C

Storage Comment: Store the HLA-DR antibody at 2-8°C (with azide) or aliquot and store at -20°C or colder (without azide).

Target Details for HLA-DR

Target: HLA-DR

Alternative Name: HLA-DR (MHC II)

Background: MAb IPO-10 defines the antigen, which appears on B cell progenitors following HLA-DR and preceding CD10, CD19, CD22, CD37 and cym. It is expressed on resting B cells and than reappears and persists in cytoplasm and on cell surface until cytoplasmic Ig appears. It is a useful antibody for diagnostics of neoplasms of B cell origins. It reacts with human B cell lines Daudi, Raji, Namalva, EB-3, RPMI-8226 (50 % of cells). The mAb does not label T cell lines, blood granulocytes, thymocytes or bone marrow stromal fibroblasts. No significant changes are detected after PHA or ConA stimulation while LPS and PWM stimulated cultures after 18-48h show decreased number of antigen-positive cells but in final terms of cultivation antigen is expressed again. This mAb labels B cell leukemias and some lymphomas. Hairy cell leukemia strongly reacts and 70 % of B cell CLL and some B-NHL were also positive. IPO-10 reacts with AMML cells and in a majority of Hodgkin's disease cases a significant percentage of affected lymph node cells were detected.

Pathways: Human Leukocyte Antigen (HLA) in Adaptive Immune Response